These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15781666)

  • 21. Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells.
    Chen G; Wang K; Yang BY; Tang B; Chen JX; Hua ZC
    Int J Oncol; 2012 Jan; 40(1):139-47. PubMed ID: 21947421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
    Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
    Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase.
    Li L; Wang J; Ye RD; Shi G; Jin H; Tang X; Yi J
    J Cell Physiol; 2008 Nov; 217(2):486-93. PubMed ID: 18636556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1.
    Chelbi-alix MK; Bobé P; Benoit G; Canova A; Pine R
    Oncogene; 2003 Dec; 22(57):9121-30. PubMed ID: 14668793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity.
    Diaz Z; Laurenzana A; Mann KK; Bismar TA; Schipper HM; Miller WH
    Leukemia; 2007 Oct; 21(10):2117-27. PubMed ID: 17690699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Experimental study of low dose arsenic trioxide in treatment of patients with acute promyelocytic leukemia].
    Jia PM; Zhu Q; Yu Y; Chen GQ; Chen SJ; Chen Z; Wang ZY; Tong JH
    Ai Zheng; 2002 Apr; 21(4):337-40. PubMed ID: 12452006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Catalase activity and arsenic sensitivity in acute leukemia.
    Coe E; Schimmer AD
    Leuk Lymphoma; 2008 Oct; 49(10):1976-81. PubMed ID: 18949620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased nuclear expression and transactivation of vitamin D receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells.
    Amano Y; Cho Y; Matsunawa M; Komiyama K; Makishima M
    J Steroid Biochem Mol Biol; 2009 Apr; 114(3-5):144-51. PubMed ID: 19429444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death.
    Tarkanyi I; Dudognon C; Hillion J; Pendino F; Lanotte M; Aradi J; Ségal-Bendirdjian E
    Leukemia; 2005 Oct; 19(10):1806-11. PubMed ID: 16107885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.
    Testa U; Grignani F; Samoggia P; Zanetti C; Riccioni R; Lo Coco F; Diverio D; Felli N; Passerini CG; Grell M; Pelicci PG; Peschle C
    J Clin Invest; 1998 May; 101(10):2278-89. PubMed ID: 9593784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chloroquine aggravates the arsenic trioxide (As2O3)-induced apoptosis of acute promyelocytic leukemia NB4 cells via inhibiting lysosomal degradation in vitro.
    Liu DM; Zhang XD; Yang L
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6412-6421. PubMed ID: 30338810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of 22-oxa-1,25-dihydroxyvitamin D(3), a vitamin D(3) derivative, with vitamin K(2) (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cells.
    Funato K; Miyazawa K; Yaguchi M; Gotoh A; Ohyashiki K
    Leukemia; 2002 Aug; 16(8):1519-27. PubMed ID: 12145693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of arsenic trioxide administration styles on leukocytosis.
    Zhou J; Meng R; Sui XH; Meng L; Yang BF
    Chin Med Sci J; 2006 Jun; 21(2):111-4. PubMed ID: 16845799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro study on arsenic trioxide-inducing apoptosis in primary acute promyelocytic leukemie cells].
    Tang W; Chen G; Shen Z; Chen L; Shi X; Jia P; Shi G; Ni J; Chen S; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 1997 Dec; 18(12):623-6. PubMed ID: 15625759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.
    Cheng X; Quintás-Cardama A; Golemovic M; Zingaro R; Gao MZ; Freireich EJ; Andreeff M; Kantarjian HM; Verstovsek S
    Anticancer Res; 2012 Jul; 32(7):2871-80. PubMed ID: 22753750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.
    Rusiniak ME; Yu M; Ross DT; Tolhurst EC; Slack JL
    Cancer Res; 2000 Apr; 60(7):1824-9. PubMed ID: 10766166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PML/RAR alpha+ U937 mutant and NB4 cell lines: retinoic acid restores the monocytic differentiation response to vitamin D3.
    Testa U; Grignani F; Barberi T; Fagioli M; Masciulli R; Ferrucci PF; Seripa D; Camagna A; Alcalay M; Pelicci PG
    Cancer Res; 1994 Aug; 54(16):4508-15. PubMed ID: 7519122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
    Wu XX; Ogawa O; Kakehi Y
    Int J Oncol; 2004 Jun; 24(6):1489-97. PubMed ID: 15138592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.
    Golemovic M; Quintás-Cardama A; Manshouri T; Orsolic N; Duzkale H; Johansen M; Freireich EJ; Kantarjian H; Zingaro RA; Verstovsek S
    Invest New Drugs; 2010 Aug; 28(4):402-12. PubMed ID: 19468689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.